Pneumothorax in cystic fibrosis
- PMID: 25337406
- PMCID: PMC4203988
- DOI: 10.3978/j.issn.2072-1439.2014.09.27
Pneumothorax in cystic fibrosis
Abstract
Pneumothorax is recognized as a common and life-threatening complication in cystic fibrosis (CF) patients, especially in those who are infected with P. aeruginosa, B. cepacia or Aspergillus, need enteral feeding, are diagnosed as suffering from allergic bronchopulmonary aspergillosis (ABPA), developed massive hemoptysis, and their respiratory function is seriously compromised. Structural impairment and altered airflow dynamics in the lungs of CF patients are considered as the main predisposing factors, but also inhaled medications and non-invasive positive pressure ventilation (NIPPV) could increase the risk of pneumothorax. Clinical presentation could range from dramatic to very mild. Management of spontaneous pneumothorax occurring to patients with CF is essentially similar to that for non-CF patients. Therapeutic options include intercostal tube drainage, video-assisted thoracoscopic surgery (VATS), and medical or surgical pleurodesis. Pneumothorax increases both short- and long-term morbidity and mortality in CF patients and causes significant deterioration of their quality of life.
Keywords: Cystic fibrosis (CF); antibiotics, macrolides; pneumothorax.
Figures
References
-
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry: 2005 Annual data report to the center directors. Bethesda, MD: Cystic Fibrosis Foundation; 2006
-
- Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73. - PubMed
-
- Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999;79:S3-22. - PubMed
Publication types
LinkOut - more resources
Full Text Sources